Phase I trial of GRC 17536.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2011
At a glance
- Drugs GRC 17536 (Primary)
- Indications Pain; Respiratory tract disorders
- Focus Adverse reactions
- Sponsors Glenmark Pharmaceuticals Ltd
- 17 Feb 2011 Glenmark reports that the trial is expected to be initiated in the Netherlands in the near future.
- 17 Feb 2011 Planned End Date is 1 Dec 2011.
- 30 Aug 2010 Glenmark plans to file the Phase 1 application in January 2011, according to a media release.